logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Reports Phase 3 CheckMate -227 Trial Results - Quick Facts

Bristol-Myers Squibb Company (BMY) said Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo plus low-dose Yervoy met the co-primary endpoint of overall survival, demonstrating a superior benefit versus chemotherapy in first-line non-small cell lung cancer patients whose tumors express PD-L1 =1%. In an exploratory analysis of patients in Part 1b whose tumors do not express PD-L1, a survival benefit was also observed with Opdivo plus low-dose Yervoy.

However, part 2 of the CheckMate -227 trial, evaluating Opdivo plus chemotherapy, did not meet the pre-specified primary endpoint of overall survival versus chemotherapy in patients with non-squamous histology, regardless of PD-L1 status.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tyson Foods, Inc. (TSN) reported third quarter adjusted net income per share attributable to company of $1.40 compared to $1.47, a year ago. On average, 12 analysts polled by Thomson Reuters expected the company to report profit per share of $0.94, for the quarter. Analysts' estimates typically exclude... Tailored Brands Inc., which owns menswear brands Men's Wearhouse and Jos. A. Bank, has filed for bankruptcy protection, severely hit by sluggish demand amid the coronavirus woes. The company filed for chapter 11 protection in the U.S. Bankruptcy Court for the Southern District of Texas to implement financial restructuring plan. Shares of HSBC Holdings Plc (HSBC, HSBA.L) were down in London and Hong Kong trading after the Asia-focused British lender reported Monday sharply lower profit in its second quarter, hurt by higher expected credit losses, weak revenues as well as the absence of prior year gain. For fiscal 2020, the company projects expected credit losses or ECL charge in the range of $8 billion to $13 billion.
Follow RTT